Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR.

J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.

2.
3.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD.

Gynecol Oncol. 2015 Jun;137(3):392-400. doi: 10.1016/j.ygyno.2015.03.008. Epub 2015 Mar 17. Review.

PMID:
25792179
4.

Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Dhillon S.

Drugs. 2012 May 7;72(7):917-30. doi: 10.2165/11208940-000000000-00000. Review.

PMID:
22515620
5.

Dose-dense approaches to ovarian cancer treatment.

Katsumata N.

Curr Treat Options Oncol. 2015 May;16(5):21. doi: 10.1007/s11864-015-0338-4. Review.

PMID:
25859831
6.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
7.

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.

Aravantinos G, Pectasides D.

J Ovarian Res. 2014 May 19;7:57. doi: 10.1186/1757-2215-7-57. eCollection 2014. Review.

8.

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.

Monk BJ, Pujade-Lauraine E, Burger RA.

Ann Oncol. 2013 Dec;24 Suppl 10:x53-x58. doi: 10.1093/annonc/mdt472. Review.

9.

Clinical trials and future potential of targeted therapy for ovarian cancer.

Itamochi H, Kigawa J.

Int J Clin Oncol. 2012 Oct;17(5):430-40. doi: 10.1007/s10147-012-0459-8. Epub 2012 Aug 28. Review.

PMID:
22926640
10.

Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer.

Markman M.

Gynecol Oncol. 2013 Oct;131(1):241-5. doi: 10.1016/j.ygyno.2013.05.029. Epub 2013 May 30. Review.

PMID:
23726888
11.

Therapeutic strategies in epithelial ovarian cancer.

Kim A, Ueda Y, Naka T, Enomoto T.

J Exp Clin Cancer Res. 2012 Feb 13;31:14. doi: 10.1186/1756-9966-31-14. Review.

12.

Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.

Han ES, Wakabayashi M, Leong L.

Curr Treat Options Oncol. 2013 Mar;14(1):22-33. doi: 10.1007/s11864-012-0220-6. Review.

PMID:
23288484
13.

Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.

González Martín A, Bratos R, Márquez R, Alonso S, Chiva L.

Expert Rev Anticancer Ther. 2013 Feb;13(2):123-9. doi: 10.1586/era.12.165. Review.

PMID:
23406552
14.

Bevacizumab: a review of its use in advanced cancer.

Keating GM.

Drugs. 2014 Oct;74(16):1891-925. doi: 10.1007/s40265-014-0302-9. Review.

PMID:
25315029
15.

Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.

Bergamini A, Leone Roberti Maggiore U, Ferrero S, Rabaiotti E, Viganò R, Petrone M, De Marzi P, Salvatore S, Candiani M, Mangili G.

Expert Opin Investig Drugs. 2015 Mar;24(3):345-62. doi: 10.1517/13543784.2015.999154. Epub 2015 Feb 1. Review.

PMID:
25640877
16.

Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.

Frampton JE.

BioDrugs. 2015 Apr;29(2):143-50. doi: 10.1007/s40259-015-0125-6. Review.

PMID:
25899311
17.

Critical appraisal of bevacizumab in the treatment of ovarian cancer.

Yoshida H, Yabuno A, Fujiwara K.

Drug Des Devel Ther. 2015 Apr 28;9:2351-8. doi: 10.2147/DDDT.S83275. eCollection 2015. Review.

18.

Contemporary use of bevacizumab in ovarian cancer.

Miyake TM, Sood AK, Coleman RL.

Expert Opin Biol Ther. 2013 Feb;13(2):283-94. doi: 10.1517/14712598.2012.745508. Epub 2012 Nov 29. Review.

19.

The changing landscape of therapeutic strategies for recurrent ovarian cancer.

Baumann KH, Wagner U, du Bois A.

Future Oncol. 2012 Sep;8(9):1135-47. doi: 10.2217/fon.12.112. Review.

PMID:
23030488
20.

Farletuzumab in epithelial ovarian carcinoma.

Spannuth WA, Sood AK, Coleman RL.

Expert Opin Biol Ther. 2010 Mar;10(3):431-7. doi: 10.1517/14712591003592069. Review.

PMID:
20092424
Items per page

Supplemental Content

Write to the Help Desk